MASH / NASH: key endpoint results by drug
The key endpoints of MASH / NASH trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the MASH / NASH page.
MASH resolution without fibrosis worsening
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| pemvidutide | 52.1%a | 19.1% | +33 | pemvidutide 1.8mg · wk 24 | NCT05989711 Phase 2, primary |
| Resmetirom | 27.4% | 14.7% | +12.7 | wk 36 · n 73 | NCT02912260 Phase 2, secondary |
Drugs checked with no result here: 33 not reported, 2 not posted, 5 trial running.
Fibrosis stage, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Omega-3-acid ethyl esters (Lovaza) | 0.3 | 0.2 | +0.1 | wk 78 · n 46 | NCT00760513 Phase 4, primary |
| Tesamorelin | 0 | 0 | ±0 | wk 52 · n 18 | NCT03375788 Phase 2, secondary |
Drugs checked with no result here: 31 not reported, 3 not posted, 6 trial running.
Liver fat (MRI-PDFF), change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Ezetimibe | 11.6% | 16.4% | −4.8 | wk 24 · n 23 | NCT01766713 Phase 2, primary |
| Omega-3-acid ethyl esters (Lovaza) | -7.9% | -4.6% | −3.3 | wk 78 · n 46 | NCT00760513 Phase 4, primary |
| Resmetirom | -8.2% | -2.9% | −5.3 | wk 36 · n 74 | NCT02912260 Phase 2, secondary |
| survodutide | -13.0% | -1.9% | −11.1 | 6.0 mg · wk 48 · n 51 | NCT04771273 Phase 2, secondary |
Drugs checked with no result here: 31 not reported, 6 trial running, 1 not posted.
ALT, change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| Resmetirom | -15.4 | 11 | −26.4 | wk 36 · n 78 | NCT02912260 Phase 2, secondary |
| Sitagliptin | 34 | 28.5 | +5.5 | wk 24 · n 25 | NCT01963845 Phase 2, secondary |
Drugs checked with no result here: 32 not reported, 2 not posted, 6 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 42 approved or late-stage drugs with a featured trial in MASH / NASH were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.